LegalMay 19, 2026, 05:07 PM
Cardiff Oncology Sues NMS Over Onvansertib License Dispute
AI Summary
Cardiff Oncology, Inc. has filed a lawsuit against Nerviano Medical Sciences S.r.L (NMS) in the United States District Court for the Southern District of California. The lawsuit disputes NMS's allegation that Cardiff materially breached their license agreement for onvansertib. Cardiff seeks injunctive relief to compel NMS to continue performing under the agreement and a declaratory judgment that Cardiff did not commit a breach, specifically regarding the inventorship on U.S. Patent Nos. 12,144,813 and 12,263,173.
Key Highlights
- Cardiff Oncology filed a lawsuit against Nerviano Medical Sciences S.r.L (NMS) in the U.S. District Court for the Southern District of California.
- The lawsuit disputes NMS's allegation that Cardiff Oncology materially breached their license agreement for onvansertib.
- Cardiff Oncology seeks injunctive relief requiring NMS to continue performing under the agreement.
- The company also seeks a declaratory judgment that it did not breach the agreement.
- The dispute stems from NMS's claim that Cardiff Oncology failed to name an NMS employee as a joint inventor on U.S. Patent Nos. 12,144,813 and 12,263,173.
- Cardiff Oncology maintains there was no breach and the agreement does not require naming NMS employees on inventions made exclusively by the company.
Price Impact
More from CRDF